Brief: CG Oncology Announces First Patient Dosed In PIVOT-006 Phase 3 Clinical Trial Of Cretostimogene In Intermediate-Risk Non-Muscle Invasive Bladder Cancer

CG Oncology

27/02/2024 13:10

Feb 27 (Reuters) - CG Oncology Inc  CGON.O :
    * CG ONCOLOGY ANNOUNCES FIRST PATIENT DOSED IN PIVOT-006
PHASE 3
CLINICAL TRIAL OF CRETOSTIMOGENE IN INTERMEDIATE-RISK NON-MUSCLE
INVASIVE BLADDER CANCER
    * CG ONCOLOGY INC - PRIMARY ENDPOINT OF PIVOT-006 PHASE 3
CLINICAL
TRIAL IS OVERALL RECURRENCE-FREE SURVIVAL

Source text for Eikon:  ID:nGNX73fqP7 
Further company coverage:  CGON.O 

 ((Reuters.Briefs@thomsonreuters.com;))